Alto Neuroscience, Inc. ANRO
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -52.88% | -29.88% | -17.60% | -2.94% | -8.37% |
| Total Depreciation and Amortization | 4.75% | 9.02% | 17.01% | 31.67% | 51.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.08% | 31.11% | 10.80% | 14.08% | 24.25% |
| Change in Net Operating Assets | 159.04% | 652.40% | 186.92% | -99.19% | -170.16% |
| Cash from Operations | -48.52% | -23.97% | -17.56% | -9.16% | -16.00% |
| Capital Expenditure | -4.91% | 63.78% | 70.35% | 98.84% | 72.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -4.91% | 63.78% | 70.35% | 98.84% | 72.41% |
| Total Debt Issued | -100.00% | -100.00% | -96.42% | 1,535.04% | 1,535.04% |
| Total Debt Repaid | 100.00% | 100.00% | 100.00% | -- | -- |
| Issuance of Common Stock | 66,737.25% | 54,226.75% | 45,369.60% | -63.20% | -99.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -769.84% | -689.17% | -515.81% | 74.44% | 86.92% |
| Cash from Financing | 2,527.42% | 1,385.74% | 1,517.04% | -55.72% | -94.44% |
| Foreign Exchange rate Adjustments | 52.17% | 34.62% | 14.29% | -172.73% | -76.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 513.64% | 311.14% | 330.75% | -90.42% | -133.52% |